| Neoplasm by Special Category altered in cohorts of …ALTERED_INderived200 of 899show all (up to 200) |
|---|
| ← altered in cohorts of | AVPR1A 70 / 92 cases (76 %) · ssm · TCGA-ACC | — | — | Adrenal Cortical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | BAZ2A 70 / 92 cases (76 %) · ssm · TCGA-ACC | — | — | Adrenal Cortical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CAND1 70 / 92 cases (76 %) · ssm · TCGA-ACC | — | — | Adrenal Cortical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | HSD17B6 70 / 92 cases (76 %) · ssm · TCGA-ACC | — | — | Adrenal Cortical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | NACA 70 / 92 cases (76 %) · ssm · TCGA-ACC | — | — | Adrenal Cortical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | AGAP2 69 / 92 cases (75 %) · ssm · TCGA-ACC | — | — | Adrenal Cortical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ATP23 69 / 92 cases (75 %) · ssm · TCGA-ACC | — | — | Adrenal Cortical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ATP5F1B 69 / 92 cases (75 %) · ssm · TCGA-ACC | — | — | Adrenal Cortical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | AVIL 69 / 92 cases (75 %) · ssm · TCGA-ACC | — | — | Adrenal Cortical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | BIN2 69 / 92 cases (75 %) · ssm · TCGA-ACC | — | — | Adrenal Cortical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CDK4 69 / 92 cases (75 %) · ssm · TCGA-ACC | — | — | Adrenal Cortical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CTDSP2 69 / 92 cases (75 %) · ssm · TCGA-ACC | — | — | Adrenal Cortical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CYP27B1 69 / 92 cases (75 %) · ssm · TCGA-ACC | — | — | Adrenal Cortical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | DYRK2 69 / 92 cases (75 %) · ssm · TCGA-ACC | — | — | Adrenal Cortical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | EEF1AKMT3 69 / 92 cases (75 %) · ssm · TCGA-ACC | — | — | Adrenal Cortical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | FRS2 69 / 92 cases (75 %) · ssm · TCGA-ACC | — | — | Adrenal Cortical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | IL22 69 / 92 cases (75 %) · ssm · TCGA-ACC | — | — | Adrenal Cortical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | MARCHF9 69 / 92 cases (75 %) · ssm · TCGA-ACC | — | — | Adrenal Cortical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | METTL1 69 / 92 cases (75 %) · ssm · TCGA-ACC | — | — | Adrenal Cortical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | OS9 69 / 92 cases (75 %) · ssm · TCGA-ACC | — | — | Adrenal Cortical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PRIM1 69 / 92 cases (75 %) · ssm · TCGA-ACC | — | — | Adrenal Cortical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PTGES3 69 / 92 cases (75 %) · ssm · TCGA-ACC | — | — | Adrenal Cortical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | RBMS2 69 / 92 cases (75 %) · ssm · TCGA-ACC | — | — | Adrenal Cortical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | TSFM 69 / 92 cases (75 %) · ssm · TCGA-ACC | — | — | Adrenal Cortical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | TSPAN31 69 / 92 cases (75 %) · ssm · TCGA-ACC | — | — | Adrenal Cortical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ZBTB39 69 / 92 cases (75 %) · ssm · TCGA-ACC | — | — | Adrenal Cortical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ANKRD52 68 / 92 cases (74 %) · ssm · TCGA-ACC | — | — | Adrenal Cortical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ARHGAP9 68 / 92 cases (74 %) · ssm · TCGA-ACC | — | — | Adrenal Cortical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ARHGEF25 68 / 92 cases (74 %) · ssm · TCGA-ACC | — | — | Adrenal Cortical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | B4GALNT1 68 / 92 cases (74 %) · ssm · TCGA-ACC | — | — | Adrenal Cortical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | BEST3 68 / 92 cases (74 %) · ssm · TCGA-ACC | — | — | Adrenal Cortical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | C12orf66 68 / 92 cases (74 %) · ssm · TCGA-ACC | — | — | Adrenal Cortical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CELA1 68 / 92 cases (74 %) · ssm · TCGA-ACC | — | — | Adrenal Cortical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CPM 68 / 92 cases (74 %) · ssm · TCGA-ACC | — | — | Adrenal Cortical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CSRNP2 68 / 92 cases (74 %) · ssm · TCGA-ACC | — | — | Adrenal Cortical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | DCTN2 68 / 92 cases (74 %) · ssm · TCGA-ACC | — | — | Adrenal Cortical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | DDIT3 68 / 92 cases (74 %) · ssm · TCGA-ACC | — | — | Adrenal Cortical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | DPY19L2 68 / 92 cases (74 %) · ssm · TCGA-ACC | — | — | Adrenal Cortical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | DTX3 68 / 92 cases (74 %) · ssm · TCGA-ACC | — | — | Adrenal Cortical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ERBB3 68 / 92 cases (74 %) · ssm · TCGA-ACC | — | — | Adrenal Cortical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ESYT1 68 / 92 cases (74 %) · ssm · TCGA-ACC | — | — | Adrenal Cortical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | GLI1 68 / 92 cases (74 %) · ssm · TCGA-ACC | — | — | Adrenal Cortical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | GLS2 68 / 92 cases (74 %) · ssm · TCGA-ACC | — | — | Adrenal Cortical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | GNS 68 / 92 cases (74 %) · ssm · TCGA-ACC | — | — | Adrenal Cortical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | GPR182 68 / 92 cases (74 %) · ssm · TCGA-ACC | — | — | Adrenal Cortical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | GRIP1 68 / 92 cases (74 %) · ssm · TCGA-ACC | — | — | Adrenal Cortical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | HDAC7 68 / 92 cases (74 %) · ssm · TCGA-ACC | — | — | Adrenal Cortical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | HIGD1C 68 / 92 cases (74 %) · ssm · TCGA-ACC | — | — | Adrenal Cortical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | IL26 68 / 92 cases (74 %) · ssm · TCGA-ACC | — | — | Adrenal Cortical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | INHBC 68 / 92 cases (74 %) · ssm · TCGA-ACC | — | — | Adrenal Cortical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | INHBE 68 / 92 cases (74 %) · ssm · TCGA-ACC | — | — | Adrenal Cortical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | KIF5A 68 / 92 cases (74 %) · ssm · TCGA-ACC | — | — | Adrenal Cortical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | KRT74 68 / 92 cases (74 %) · ssm · TCGA-ACC | — | — | Adrenal Cortical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | KRT75 68 / 92 cases (74 %) · ssm · TCGA-ACC | — | — | Adrenal Cortical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | KRT84 68 / 92 cases (74 %) · ssm · TCGA-ACC | — | — | Adrenal Cortical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | LETMD1 68 / 92 cases (74 %) · ssm · TCGA-ACC | — | — | Adrenal Cortical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | LGR5 68 / 92 cases (74 %) · ssm · TCGA-ACC | — | — | Adrenal Cortical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | LRRC10 68 / 92 cases (74 %) · ssm · TCGA-ACC | — | — | Adrenal Cortical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | LRRC43 68 / 92 cases (74 %) · ssm · TCGA-ACC | — | — | Adrenal Cortical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | MDM2 68 / 92 cases (74 %) · ssm · TCGA-ACC | — | — | Adrenal Cortical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | METTL7A 68 / 92 cases (74 %) · ssm · TCGA-ACC | — | — | Adrenal Cortical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | MSRB3 68 / 92 cases (74 %) · ssm · TCGA-ACC | — | — | Adrenal Cortical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | MYO1A 68 / 92 cases (74 %) · ssm · TCGA-ACC | — | — | Adrenal Cortical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | NAB2 68 / 92 cases (74 %) · ssm · TCGA-ACC | — | — | Adrenal Cortical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | NDUFA4L2 68 / 92 cases (74 %) · ssm · TCGA-ACC | — | — | Adrenal Cortical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | NEMP1 68 / 92 cases (74 %) · ssm · TCGA-ACC | — | — | Adrenal Cortical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | NUP107 68 / 92 cases (74 %) · ssm · TCGA-ACC | — | — | Adrenal Cortical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | NXPH4 68 / 92 cases (74 %) · ssm · TCGA-ACC | — | — | Adrenal Cortical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PCED1B 68 / 92 cases (74 %) · ssm · TCGA-ACC | — | — | Adrenal Cortical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PIP4K2C 68 / 92 cases (74 %) · ssm · TCGA-ACC | — | — | Adrenal Cortical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | POU6F1 68 / 92 cases (74 %) · ssm · TCGA-ACC | — | — | Adrenal Cortical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | RAB3IP 68 / 92 cases (74 %) · ssm · TCGA-ACC | — | — | Adrenal Cortical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | RAP1B 68 / 92 cases (74 %) · ssm · TCGA-ACC | — | — | Adrenal Cortical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | RDH16 68 / 92 cases (74 %) · ssm · TCGA-ACC | — | — | Adrenal Cortical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | RPL41 68 / 92 cases (74 %) · ssm · TCGA-ACC | — | — | Adrenal Cortical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | RXYLT1 68 / 92 cases (74 %) · ssm · TCGA-ACC | — | — | Adrenal Cortical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SCN8A 68 / 92 cases (74 %) · ssm · TCGA-ACC | — | — | Adrenal Cortical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SHMT2 68 / 92 cases (74 %) · ssm · TCGA-ACC | — | — | Adrenal Cortical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SLC11A2 68 / 92 cases (74 %) · ssm · TCGA-ACC | — | — | Adrenal Cortical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SLC35E3 68 / 92 cases (74 %) · ssm · TCGA-ACC | — | — | Adrenal Cortical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SMAGP 68 / 92 cases (74 %) · ssm · TCGA-ACC | — | — | Adrenal Cortical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SPRYD4 68 / 92 cases (74 %) · ssm · TCGA-ACC | — | — | Adrenal Cortical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SRGAP1 68 / 92 cases (74 %) · ssm · TCGA-ACC | — | — | Adrenal Cortical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | STAC3 68 / 92 cases (74 %) · ssm · TCGA-ACC | — | — | Adrenal Cortical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SUOX 68 / 92 cases (74 %) · ssm · TCGA-ACC | — | — | Adrenal Cortical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | TAC3 68 / 92 cases (74 %) · ssm · TCGA-ACC | — | — | Adrenal Cortical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | TFCP2 68 / 92 cases (74 %) · ssm · TCGA-ACC | — | — | Adrenal Cortical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | XPOT 68 / 92 cases (74 %) · ssm · TCGA-ACC | — | — | Adrenal Cortical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | YEATS4 68 / 92 cases (74 %) · ssm · TCGA-ACC | — | — | Adrenal Cortical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ZC3H10 68 / 92 cases (74 %) · ssm · TCGA-ACC | — | — | Adrenal Cortical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | FAM189B 276 / 377 cases (73 %) · ssm · TCGA-LIHC · largest of 2 cohorts | — | — | Hepatocellular Carcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | DCST2 275 / 377 cases (73 %) · ssm · TCGA-LIHC · largest of 2 cohorts | — | — | Hepatocellular Carcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | EFNA1 275 / 377 cases (73 %) · ssm · TCGA-LIHC · largest of 2 cohorts | — | — | Hepatocellular Carcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | MTX1 275 / 377 cases (73 %) · ssm · TCGA-LIHC · largest of 2 cohorts | — | — | Hepatocellular Carcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | ZBTB7B 275 / 377 cases (73 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ARHGEF2 274 / 377 cases (73 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | DPM3 274 / 377 cases (73 %) · ssm · TCGA-LIHC · largest of 2 cohorts | — | — | Hepatocellular Carcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | EFNA4 274 / 377 cases (73 %) · ssm · TCGA-LIHC · largest of 2 cohorts | — | — | Hepatocellular Carcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | KHDC4 274 / 377 cases (73 %) · ssm · TCGA-LIHC · largest of 3 cohorts | — | — | Hepatocellular Carcinoma | 3 | Observed | gdc | graph → |
| ← altered in cohorts of | KRTCAP2 274 / 377 cases (73 %) · ssm · TCGA-LIHC · largest of 2 cohorts | — | — | Hepatocellular Carcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | LENEP 274 / 377 cases (73 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | MUC1 274 / 377 cases (73 %) · ssm · TCGA-LIHC · largest of 2 cohorts | — | — | Hepatocellular Carcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | CKS1B 273 / 377 cases (72 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | DAP3 273 / 377 cases (72 %) · ssm · TCGA-LIHC · largest of 3 cohorts | — | — | Hepatocellular Carcinoma | 3 | Observed | gdc | graph → |
| ← altered in cohorts of | PYGO2 273 / 377 cases (72 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | RXFP4 273 / 377 cases (72 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SHC1 273 / 377 cases (72 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SLC27A3 273 / 377 cases (72 %) · ssm · TCGA-LIHC · largest of 2 cohorts | — | — | Hepatocellular Carcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | LMNA 272 / 377 cases (72 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | MEX3A 272 / 377 cases (72 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PMVK 272 / 377 cases (72 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | BMP1 271 / 377 cases (72 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CCT3 271 / 377 cases (72 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ETV3L 271 / 377 cases (72 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | GATAD2B 271 / 377 cases (72 %) · ssm · TCGA-LIHC · largest of 2 cohorts | — | — | Hepatocellular Carcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | ISG20L2 271 / 377 cases (72 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | LAMTOR2 271 / 377 cases (72 %) · ssm · TCGA-LIHC · largest of 2 cohorts | — | — | Hepatocellular Carcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | LRRC71 271 / 377 cases (72 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | MNDA 271 / 377 cases (72 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | NTRK1 271 / 377 cases (72 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PIWIL2 271 / 377 cases (72 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PMF1 271 / 377 cases (72 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | POLR3D 271 / 377 cases (72 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | RAB25 271 / 377 cases (72 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SEMA4A 271 / 377 cases (72 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SH2D2A 271 / 377 cases (72 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SSR2 271 / 377 cases (72 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | TMEM79 271 / 377 cases (72 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | TNFRSF10A 271 / 377 cases (72 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | UBE2Q1 271 / 377 cases (72 %) · ssm · TCGA-LIHC · largest of 2 cohorts | — | — | Hepatocellular Carcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | UBQLN4 271 / 377 cases (72 %) · ssm · TCGA-LIHC · largest of 2 cohorts | — | — | Hepatocellular Carcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | ADAM28 270 / 377 cases (72 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ARHGAP30 270 / 377 cases (72 %) · ssm · TCGA-LIHC · largest of 2 cohorts | — | — | Hepatocellular Carcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | ATF6 270 / 377 cases (72 %) · ssm · TCGA-LIHC · largest of 2 cohorts | — | — | Hepatocellular Carcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | CRABP2 270 / 377 cases (72 %) · ssm · TCGA-LIHC · largest of 2 cohorts | — | — | Hepatocellular Carcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | ETV3 270 / 377 cases (72 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | FCGR3B 270 / 377 cases (72 %) · ssm · TCGA-LIHC · largest of 2 cohorts | — | — | Hepatocellular Carcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | GLMP 270 / 377 cases (72 %) · ssm · TCGA-LIHC · largest of 2 cohorts | — | — | Hepatocellular Carcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | HAPLN2 270 / 377 cases (72 %) · ssm · TCGA-LIHC · largest of 2 cohorts | — | — | Hepatocellular Carcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | HDGF 270 / 377 cases (72 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | NIT1 270 / 377 cases (72 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | OR6Y1 270 / 377 cases (72 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PAQR6 270 / 377 cases (72 %) · ssm · TCGA-LIHC · largest of 2 cohorts | — | — | Hepatocellular Carcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | REEP4 270 / 377 cases (72 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SNAPIN 270 / 377 cases (72 %) · ssm · TCGA-LIHC · largest of 2 cohorts | — | — | Hepatocellular Carcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | USP21 270 / 377 cases (72 %) · ssm · TCGA-LIHC · largest of 2 cohorts | — | — | Hepatocellular Carcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | PRPF3 35 / 50 cases (70 %) · ssm · CDDP_EAGLE-1 | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | FCGR3A 60 / 87 cases (69 %) · ssm · APOLLO-LUAD | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | HSPA6 60 / 87 cases (69 %) · ssm · APOLLO-LUAD · largest of 2 cohorts | — | — | Lung Adenocarcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | ANP32E 34 / 50 cases (68 %) · ssm · CDDP_EAGLE-1 | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | APH1A 34 / 50 cases (68 %) · ssm · CDDP_EAGLE-1 | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | C1orf54 34 / 50 cases (68 %) · ssm · CDDP_EAGLE-1 | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CA14 34 / 50 cases (68 %) · ssm · CDDP_EAGLE-1 | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CIART 34 / 50 cases (68 %) · ssm · CDDP_EAGLE-1 | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CTXND2 34 / 50 cases (68 %) · ssm · CDDP_EAGLE-1 | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | MRPS21 34 / 50 cases (68 %) · ssm · CDDP_EAGLE-1 | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | FCGR2B 59 / 87 cases (68 %) · ssm · APOLLO-LUAD | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ASH1L 382 / 573 cases (67 %) · ssm · TCGA-LUAD · largest of 3 cohorts | — | — | Lung Adenocarcinoma | 3 | Observed | gdc | graph → |
| ← altered in cohorts of | CD84 58 / 87 cases (67 %) · ssm · APOLLO-LUAD | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | FCGR2A 58 / 87 cases (67 %) · ssm · APOLLO-LUAD | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | FCRLA 58 / 87 cases (67 %) · ssm · APOLLO-LUAD | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | FCRLB 58 / 87 cases (67 %) · ssm · APOLLO-LUAD | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | JTB 58 / 87 cases (67 %) · ssm · APOLLO-LUAD · largest of 2 cohorts | — | — | Lung Adenocarcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | RAB13 58 / 87 cases (67 %) · ssm · APOLLO-LUAD | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | RPS27 58 / 87 cases (67 %) · ssm · APOLLO-LUAD · largest of 2 cohorts | — | — | Lung Adenocarcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | SLAMF6 58 / 87 cases (67 %) · ssm · APOLLO-LUAD | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SLC39A1 58 / 87 cases (67 %) · ssm · APOLLO-LUAD · largest of 2 cohorts | — | — | Lung Adenocarcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | TNN 382 / 573 cases (67 %) · ssm · TCGA-LUAD · largest of 7 cohorts | — | — | Lung Adenocarcinoma | 7 | Observed | gdc | graph → |
| ← altered in cohorts of | TNR 382 / 573 cases (67 %) · ssm · TCGA-LUAD · largest of 6 cohorts | — | — | Lung Adenocarcinoma | 6 | Observed | gdc | graph → |
| ← altered in cohorts of | UAP1 58 / 87 cases (67 %) · ssm · APOLLO-LUAD | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | UHMK1 58 / 87 cases (67 %) · ssm · APOLLO-LUAD | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | C1orf56 33 / 50 cases (66 %) · ssm · CDDP_EAGLE-1 | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | GABPB2 33 / 50 cases (66 %) · ssm · CDDP_EAGLE-1 | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | LYSMD1 33 / 50 cases (66 %) · ssm · CDDP_EAGLE-1 | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PLEKHO1 33 / 50 cases (66 %) · ssm · CDDP_EAGLE-1 | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PSMD4 33 / 50 cases (66 %) · ssm · CDDP_EAGLE-1 | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | RFX5 33 / 50 cases (66 %) · ssm · CDDP_EAGLE-1 | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | TMOD4 33 / 50 cases (66 %) · ssm · CDDP_EAGLE-1 | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | TNFAIP8L2 33 / 50 cases (66 %) · ssm · CDDP_EAGLE-1 | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | VPS72 33 / 50 cases (66 %) · ssm · CDDP_EAGLE-1 | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | C1orf189 57 / 87 cases (66 %) · ssm · APOLLO-LUAD · largest of 2 cohorts | — | — | Lung Adenocarcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | C1orf226 57 / 87 cases (66 %) · ssm · APOLLO-LUAD | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CD48 57 / 87 cases (66 %) · ssm · APOLLO-LUAD | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | DDR2 57 / 87 cases (66 %) · ssm · APOLLO-LUAD | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | DUSP12 57 / 87 cases (66 %) · ssm · APOLLO-LUAD | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | HAX1 57 / 87 cases (66 %) · ssm · APOLLO-LUAD | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | IGSF8 57 / 87 cases (66 %) · ssm · APOLLO-LUAD | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | IL6R 57 / 87 cases (66 %) · ssm · APOLLO-LUAD | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ILF2 57 / 87 cases (66 %) · ssm · APOLLO-LUAD | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | INTS3 57 / 87 cases (66 %) · ssm · APOLLO-LUAD | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | KCNJ10 57 / 87 cases (66 %) · ssm · APOLLO-LUAD | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | KCNJ9 57 / 87 cases (66 %) · ssm · APOLLO-LUAD | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | LY9 57 / 87 cases (66 %) · ssm · APOLLO-LUAD · largest of 2 cohorts | — | — | Lung Adenocarcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | NOS1AP 57 / 87 cases (66 %) · ssm · APOLLO-LUAD | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | S100A1 57 / 87 cases (66 %) · ssm · APOLLO-LUAD | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | S100A13 57 / 87 cases (66 %) · ssm · APOLLO-LUAD | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SH2D1B 57 / 87 cases (66 %) · ssm · APOLLO-LUAD | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SLAMF1 57 / 87 cases (66 %) · ssm · APOLLO-LUAD | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SLAMF7 57 / 87 cases (66 %) · ssm · APOLLO-LUAD | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SPATA46 57 / 87 cases (66 %) · ssm · APOLLO-LUAD | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |